Background Treatment modifications, including dose escalations, dose reductions, switches, discontinuations and restarts of biologics may be necessary in the management of psoriasis but the patterns of usage are incompletely defined. Objectives To examine the treatment utilization patterns of adalimumab, etanercept and ustekinumab among biologic-na€ ıve and non-na€ ıve patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Methods The study cohort included adults with chronic plaque psoriasis who were followed up for ≥ 12 months. Treatment modifications were assessed during the first year of therapy. The time-trend method, comparing the cumulative dose (CD) patients received with the recommended cumulative dose (RCD), was used to assess dosing patterns. Concomitant use of other systemic treatments was also examined. Results In total, 2980 patients (adalimumab: 1675; etanercept: 996; ustekinumab: 309) were included; 79Á2% were biologic-na€ ıve. Over 12 months, 77Á4% of patients continued the biologic, 2Á6% restarted therapy after a break of ≥ 90 days, 2Á5% discontinued, and 17Á5% switched biologic therapy. Most patients (85Á7%) received the RCD of the biologic, although 8Á1% were exposed to a higher CD. In total, 749 (25Á1%) patients used conventional systemic therapies concomitantly with a biologic at some stage; methotrexate was used most commonly (458; 61Á2%). Of those using combination therapy, 454 (60Á6%) continued the use of the conventional systemic therapy for > 120 days after the start of the biologic. Conclusions More than one-third of patients experienced treatment modifications within the first year of initiating a biologic. Conventional systemic therapies, particularly methotrexate, were commonly used concurrently, which should be considered when evaluating treatment response and adverse events to biologics in real-world observational studies.
Summary
Background Treatment modifications, including dose escalations, dose reductions, switches, discontinuations and restarts of biologics may be necessary in the management of psoriasis but the patterns of usage are incompletely defined. Objectives To examine the treatment utilization patterns of adalimumab, etanercept and ustekinumab among biologic-na€ ıve and non-na€ ıve patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Methods The study cohort included adults with chronic plaque psoriasis who were followed up for ≥ 12 months. Treatment modifications were assessed during the first year of therapy. The time-trend method, comparing the cumulative dose (CD) patients received with the recommended cumulative dose (RCD), was used to assess dosing patterns. Concomitant use of other systemic treatments was also examined. Results In total, 2980 patients (adalimumab: 1675; etanercept: 996; ustekinumab: 309) were included; 79Á2% were biologic-na€ ıve. Over 12 months, 77Á4% of patients continued the biologic, 2Á6% restarted therapy after a break of ≥ 90 days, 2Á5% discontinued, and 17Á5% switched biologic therapy. Most patients (85Á7%) received the RCD of the biologic, although 8Á1% were exposed to a higher CD. In total, 749 (25Á1%) patients used conventional systemic therapies concomitantly with a biologic at some stage; methotrexate was used most commonly (458; 61Á2%). Of those using combination therapy, 454 (60Á6%) continued the use of the conventional systemic therapy for > 120 days after the start of the biologic. Conclusions More than one-third of patients experienced treatment modifications within the first year of initiating a biologic. Conventional systemic therapies, particularly methotrexate, were commonly used concurrently, which should be considered when evaluating treatment response and adverse events to biologics in real-world observational studies.
What's already known about this topic?
• Published evidence concerning the utilization patterns of biologic therapies for psoriasis, including dosing, switching, discontinuation and restarts is limited to biologic-na€ ıve patients.
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• Furthermore, the ability to determine the patterns of concomitant use of conventional systemic therapies with biologic therapies is confined to a few small-scale studies.
What does this study add?
• Based on a cohort of 2980 patients receiving biologic therapies for psoriasis, 33Á7% of patients experienced treatment modifications during their first year of treatment.
• There were no significant differences between biologic-na€ ıve and non-na€ ıve patients in the proportions of patients who switched, discontinued or restarted therapy.
• Conventional systemic therapies, particularly methotrexate, were commonly used concurrently with biologics.
Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. Those currently licensed for psoriasis include the tumour necrosis factor inhibitors: adalimumab, etanercept and infliximab; interleukin (IL)-17A inhibitors: secukinumab and ixekizumab; and IL-12/23 inhibitor: ustekinumab.
Although the licensed dosing regimens of biologics are established in large, randomized controlled trials, clinical practice suggests that alternative dosing regimens may be necessary. These can be categorized broadly into dose escalation, dose reduction and interrupted therapy. 1 The reasons for these adjustments may include attempts to improve effectiveness, including: dose escalation in obese patients for whom standard dosing regimens are ineffective; addressing increasing dose tolerance over time (including the development of antidrug antibodies); gaps in treatment schedules to prepare for surgery with significant risk of infection; or, following the development of adverse events. 1 A systematic review by Brezinski and Armstrong 1 identified 23 prospective clinical trials [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] that evaluated changes in dosing regimens of biologics for patients with psoriasis who were nonresponders. Among nonresponders, dose escalation with adalimumab, etanercept and ustekinumab usually resulted in greater efficacy than standard dosing regimens. 1 However, the utilization profile of biologics cannot be assessed adequately in clinical trials as these are restricted by their inclusion criteria and size, resulting in low external validity for 'real-world' psoriasis populations. 13 Several studies have reported on the utilization patterns of biologics for psoriasis based on employer-based claims databases. These studies employed different methods, resulting in a range of estimates.
14-21 For instance, Wu et al. 20 reported that 33-50% of patients required dose escalation during their first year of etanercept therapy, while Thayer et al. 14 reported that etanercept usage over 1 year of follow-up was stable and patients used 98-104% of the U.S. label-recommended doses. The diverse estimates reported from these studies are likely to be due to the different measures employed, highlighting a lack of consensus on an optimal method to evaluate dosing patterns. 22 Several small-scale studies have also reported on the utilization of biologics in U.K. clinical practice. [23] [24] [25] [26] Nevertheless, the generalizability of their findings may be limited by small sample size ranging from 46 to 169 patients. Information on dosing patterns has important economic implications. 27 In addition, changes in dosing regimen may affect clinical effectiveness and the likelihood of adverse events. For instance, a recent systematic review examining the risk of serious infection during biologic treatment of patients with rheumatoid arthritis has suggested that 'high-dose' use of biologics was associated with an increased risk of serious infection.
28
Published evidence on the utilization patterns of biologics for psoriasis is based mainly on biologic-na€ ıve patients; little is known about the utilization patterns among biologic-experienced patients. Furthermore, the addition of conventional systemic therapies used to treat psoriasis after or at the initiation of biologics has been studied in only three small-scale studies, [24] [25] [26] thereby limiting the ability to determine their pattern of use. Large-scale cohorts are required to fully understand these utilization patterns. The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a pharmacovigilance register which represents a valuable resource to assess real-world utilization patterns of biologics for psoriasis due to its size and high external validity, with over 150 participating dermatology centres. 29 The aim of this study was to examine the utilization and dosing patterns of adalimumab, etanercept and ustekinumab within the first 12 months of treatment among biologic-na€ ıve and non-na€ ıve patients with psoriasis. Concomitant therapy with other systemic treatments was also examined.
Methods
The BADBIR, established in September 2007, compares a cohort of patients with psoriasis on biologics with a similar cohort on conventional systemic therapies. Details about the design of BADBIR and the disease characteristics of its participants has been published previously. 
Follow-up assessments
Data from patients were collected at 6-month intervals during the study period. Details of biologics, including any change in dose or biologic therapy, start and stop dates, and reason for discontinuation were recorded. For adalimumab and etanercept the dosing regimen was recorded, whereas for ustekinumab, the dose and date of administration was documented. Information on any new concomitant conventional systemic therapies and their start and stop dates was also captured.
Patient selection
Adult patients with chronic plaque psoriasis, receiving adalimumab, etanercept or ustekinumab were included if they had been followed up for ≥ 12 months and had complete records of dosing information. The study time frame was from September 2007 to August 2014; the patients had to be enrolled into BADBIR before August 2013 to allow at least 12 months of follow-up for all patients. The index date (the start of observation time) was defined as the start date of the index biologic (therapy received at enrolment). Patients were classified as either biologic-na€ ıve or non-na€ ıve based on their previous exposure to biologics prior to enrolment into BADBIR. Due to the stricter eligibility criteria for use of infliximab in most of the U.K., 32 the proportion of patients managed by infliximab who fulfilled the inclusion criteria was very low (144 patients); thus patients on infliximab were excluded.
Outcome measures
The primary outcomes for the analysis were changes in medication utilization (dose escalation/reduction, switching, discontinuation and restarting therapy), which were evaluated in the first 12 months of follow-up. Patterns of use of conventional systemic therapies concomitantly with a biologic were also examined.
Continuous use of biologic therapy was defined as not having any gaps in treatment that exceeded a 90-day period. This permissible treatment gap of 90 days was used to disregard temporary treatment discontinuation due to clinical reasons, and to take into account the early U.K. licensing of etanercept as an intermittent dosing regimen with gaps of < 90 days. 33 Patients with a gap of ≥ 90 days after the index date were defined as discontinuing their index biologic and were further classified into one of three mutually exclusive groups based on the treatment patterns after the first 90-day gap: discontinued, restarted or switched therapy. Patients were classified as 'discontinued therapy' if they did not receive any biologic after the first 90-day gap; patients were classified as restarted therapy if they had a treatment gap that exceeded the 90-day period and subsequently restarted the same biologic therapy; patients were classified as switched therapy if they initiated a new biologic after the first 90-day gap. As the switching patterns could be affected by the introduction of new biologic therapies (such as ustekinumab) or the withdrawal of others (such as efalizumab), switchers were stratified over time periods (2008-09, 2010-12 and 2013-14) based on the year they switched therapy.
Dosing for each biologic was calculated as the average weekly dose; for adalimumab and etanercept, the average weekly dose was a function of the dose and dosing interval based on the recorded dosing regimen, whereas for ustekinumab the average weekly dose was a function of the dose and the intervals between the administered doses, which were calculated in number of weeks. Interval patterns for ustekinumab were assessed based on a window around the recommended dosing interval (4 AE 1 weeks for the interval of index to second dose, and 12 AE 1 weeks for the interval of second, third dose and subsequent doses).
The time-trend method, which compares the annual cumulative dose (CD) patients received with the annual recommended cumulative dose (RCD) per product prescribing information, was used to assess dosing patterns. 34 The CD that a patient received over the first year of therapy was calculated as a time-varying variable taking into consideration any gaps in treatment of < 90 days. The annual CD was then compared with the annual RCD. The annual RCDs according to National Institute for Health and Care Excellence (NICE) guidelines 32 were: 2600 mg (50 mg 9 52 weeks) for etanercept; 1120 mg [80 mg + (40 mg 9 26 weeks)] for adalimumab and; 270 mg (45 mg 9 6 doses), or 540 mg (90 mg 9 6 doses) if > 100 kg, for ustekinumab. Bridging therapy was defined as conventional systemic therapy started before or at the time of biologic initiation and used concomitantly with the biologic for ≤ 120 days, whereas rescue therapy was defined as additional conventional systemic therapy started after the first 120 days of biologic therapy (Fig. 1) . The 120-day threshold was chosen based on clinical expert opinion and biologic therapy guidelines which state that therapy with adalimumab, etanercept or ustekinumab can be continued beyond 12-16 weeks only in those patients who respond according to criteria determined by NICE. 32 
Data analysis
Patients were assigned to one of three unique biologic cohorts based on their index biologic and recorded as either biologicna€ ıve or non-na€ ıve. Patient demographics and disease characteristics on enrolment were analysed. Descriptive analysis was used to summarize the data (mean AE SD or frequencies) as appropriate. Differences between biologic cohorts and between biologic-na€ ıve and non-na€ ıve patients within each cohort were tested using analysis of variance (ANOVA) and ttests, respectively, or their nonparametric equivalentsKruskall-Wallis and Mann-Whitney U-tests -respectively, for continuous data and chi-square tests for categorical data. Chisquare tests were also used to assess between-cohort and within-cohort differences for dose escalation/reduction, restart, switching and discontinuation. Given the large cohort studied and the multiple tests, P ≤ 0Á01 was considered to be statistically significant. All statistical analyses were conducted using Stata v.13 (Stata Corp, College Station, TX, U.S.A.).
Results
Overall, 2980 patients met the study criteria, including 1675 (56Á2%) on adalimumab; 996 (33Á4%) on etanercept and 309 (10Á4%) on ustekinumab (Fig. 2) . The mean AE SD age of patients and disease duration were 45Á9 AE 12Á5 years, and 22Á9 AE 12Á3 years, respectively, with 60Á9% male. Mean AE SD PASI and DLQI scores at enrolment were 16Á4 AE 7Á8 and 17Á1 AE 7Á5, respectively, with 12Á4% suffering from unstable psoriasis. The mean AE SD body mass index (BMI) was 31Á0 AE 7Á2 kg m À2 , with 46% having a BMI > 30 kg m À2 . In total, 75Á9% of patients had one or more comorbidities. Baseline demographic and disease characteristics are summarized in Table 1 .
Utilization patterns
Over the 12-month follow-up period 77Á4% of patients continuously used their index biologic and had no gaps in therapy of ≥ 90 day (Fig. 3) , with no significant difference in the proportion of patients who continuously used their index biologic between na€ ıve and non-na€ ıve patients within each biologic cohort. Fourteen per cent of patients discontinued treatment due to lack of effectiveness; 4Á6% as a result of adverse events; and 4Á1% for other reasons (data not shown).
In total, 673 (22Á6%) patients had a ≥ 90-day gap in therapy. Of these patients, 521 (77Á4%) patients switched to an alternative biologic therapy, 78 (11Á6%) patients restarted therapy after a break of ≥ 90 days, and 74 (11Á0%) patients discontinued therapy. Specifically, 239 [14Á3% (percentages are of all patients on the respective biologic)], 234 (23Á5%) and 48 (15Á5%) of patients on adalimumab, etanercept and ustekinumab, respectively, switched therapy (P < 0Á001); 55 (3Á3%), 17 (1Á7%) and 6 (1Á9%) of patients on adalimumab, etanercept and ustekinumab, respectively, restarted therapy (P = 0Á001); and 46 (2Á7%), 16 (1Á6%) and 12 (3Á9%) of patients on adalimumab, etanercept and ustekinumab, respectively, discontinued therapy (P = 0Á002; Fig. 3 ). There was no significant difference in the proportion of patients who switched, restarted or discontinued therapy between na€ ıve and non-na€ ıve patients within each biologic cohort. Treatment switching patterns among those that switched therapy are summarized in Table 2 .
Dosing patterns
Overall, 85Á7% of patients received the RCD of the biologic therapy, with 6Á2% of patients being exposed to a lower CD and 8Á1% of patients being exposed to a higher CD (Table 3) . Specifically, 5Á2%, 2Á5% and 30Á0% of the patients on etanercept, adalimumab and ustekinumab, respectively, were exposed to a lower CD, while 11Á4%, 4Á5% and 17Á7%, respectively, were exposed to a higher CD (P < 0Á001; Table 3 ). A significant difference in the dosing pattern between etanercept-na€ ıve and non-na€ ıve patients was identified (Table 3) , with a higher proportion of na€ ıve patients being exposed to the RCD. In contrast, there was no significant difference in the dosing pattern between na€ ıve and non-na€ ıve patients on adalimumab and ustekinumab. In all but one case, higher rates for changes in utilization of ustekinumab were due to differences with administration intervals rather than prescribed dose.
Interestingly, patients exposed to a higher CD had a higher mean BMI at baseline compared with patients exposed to a lower CD or those receiving the RCD (32Á0 AE 7Á0 kg m À2 , 30Á6 AE 6Á5 kg m À2 and 30Á6 AE 6Á9 kg m À2 , respectively, P = 0Á038). Patients receiving a higher CD also had a higher mean body weight at baseline compared with patients exposed to a lower CD or those receiving the RCD (94Á0 AE 21Á1 kg, 88Á8 AE 20Á6 kg, and 89Á9 AE 20Á7 kg, respectively, P = 0Á029). Furthermore, those exposed to a higher CD were more likely to have unstable psoriasis at baseline compared with those receiving a lower CD or the RCD (18Á8%, 13Á2% and 10Á8%, respectively, P = 0Á019).
Pattern of use of conventional systemic therapies concomitantly with biologics
In total, 749 (25Á1%) patients used conventional systemic therapies concomitantly with a biologic therapy during the first 12 months of treatment. Specifically, 427 (25Á5%), 252 (25Á3%) and 70 (22Á7%) patients on adalimumab, etanercept and ustekinumab, respectively, used conventional systemic therapies concomitantly with a biologic (P = 0Á556). The most commonly prescribed concomitant therapies were methotrexate (458; 61Á2%) and ciclosporin (219; 29Á2%). However, acitretin (72; 9Á6%), fumaric acid esters (37; 4Á9%) and hydroxycarbamide (15; 2Á0%) were also coprescribed. Fifty-two patients (1Á7%) were treated with different conventional systemic therapies at different times, e.g. ciclosporin as a bridging therapy and methotrexate added later as a rescue therapy (Table 4) . Of those patients receiving combination therapy, 454 (60Á6%) continued the use of the conventional systemic therapy for > 120 days after the start of biologic therapy, whereas 160 (21Á4%) and 152 (20Á3%) used the conventional systemic therapy as bridging or rescue therapy, respectively. Among patients who used the conventional systemic therapy either for > 120 days or as rescue therapy, methotrexate was used most commonly, whereas ciclosporin was most frequently used as bridging therapy (Table 4 ). Interestingly, of those patients receiving combination therapy, 227 (30Á3%) patients had psoriatic arthritis. There was no difference in the proportion of patients using concomitant conventional systemic therapies between those exposed to higher CD, lower CD or the RCD.
Discussion
In this cohort study examining the real-world utilization and dosing patterns of adalimumab, etanercept and ustekinumab, over one-third of patients experienced some form of treatment modification during the first 12 months of treatment. There were no significant differences in the proportion of biologicna€ ıve and non-na€ ıve patients who switched, restarted or discontinued therapy. One of the most notable findings was that conventional systemic therapies, particularly methotrexate, were commonly used concurrently with biologics, with 15% of patients continuing their use for > 120 days after the start of the biologic.
To our knowledge, this is the first study that has reported on the utilization and dosing pattern of biologics among biologic-na€ ıve and non-na€ ıve patients with psoriasis. Our findings differ from earlier reports of etanercept and adalimumab treatment patterns in U.S. health plans in which a higher proportion of patients who had gaps in therapy either discontinued or restarted their index biologic; and only 6-20% of patients switched to another biologic, 16, 17, 19, 21 whereas we found that 77Á4% of patients who had a ≥ 90-day gap in therapy switched to an alternative biologic.
Using the time-trend method, which provides the most comprehensive information on dosing patterns in clinical practice, 34 we robustly assessed the dosing patterns of adalimumab, etanercept and ustekinumab over time. The timetrend method has the advantage of examining dose escalation/ reduction relative to the RCD, taking into account the cumulative period of exposure to the drug. Other studies 14, 15, 20 have used different analytical methods that are associated with limitations in determining exposure to treatments, which may lead to different interpretations of the usage patterns of biologics. For instance, Wu et al. 20 defined the absence of dose decrease as a dose increase; while Feldman et al. 15 used a threshold of 25% to define a significant dose increase (or decrease) to which the rates of dose escalation/reduction may be sensitive, with fewer patients experiencing dose escalation/reduction with higher thresholds. This approach is often used when the objective is to evaluate dose escalation/reduction beyond a certain threshold, 34 but can fail to distinguish between multiple changes over time and therefore may account only partially for dose escalation/reduction. 34 The results of our study demonstrate that the majority of patients with psoriasis in the U.K. receive the RCD of biologic therapy. The low proportion of patients with a CD higher than the RCD is likely to be related to the system of public funding for biologic therapies in the U.K., where applications for uptitration are often not accepted. 33 Interestingly, a significantly lower proportion of patients on ustekinumab were exposed to the RCD compared with patients on adalimumab or etanercept. This may be due in part to the relatively wide dosing schedule of ustekinumab; hence a delay in the administration of one dose would increase the intervals between doses and ultimately the patient would be exposed to a CD less than the RCD.
Another study of 374 patients with psoriasis who were initiated on ustekinumab reported that of those who received their third ustekinumab dose, 75Á9% had their third dose administered as expected, while the rest had their dose administered earlier (8Á7%) or later (15Á4%) than expected. 35 The Fig 3. Rates of continuous use, restart, switching and discontinuation of biologic therapy over the first 12 months of therapy. rates of patients receiving their third dose later than expected is slightly lower than that observed in our analysis because of the use of a wider window around the recommended dosing intervals. The major strengths of our study are the prospective realworld cohort study design and detailed data capture allowing the analysis of information that may affect study outcomes, such as concurrent conventional systemic therapies. Additionally, the large sample size and the broad inclusion criteria ensure high external validity. As BADBIR was established primarily as a pharmacovigilance register, limitations to studying medication utilization patterns are inherent to the study design, such as information on patients' adherence to treatment and the intention behind use of concomitant conventional systemic therapies. An inherent limitation to an observational study is nonrandomization, which, in turn, may introduce selection bias.
Although biologic treatment for psoriasis has been associated with reduced frequency of medical service utilization and reduced healthcare costs, 36 this study highlights the frequent use of conventional systemic therapies concomitantly with biologics in routine clinical practice; hence, further studies are needed to assess the impact of dosage increase and the concomitant use of conventional systemic therapies on total healthcare costs. Moreover, studies assessing whether dosage increases are associated with improved effectiveness are warranted, because of the potential to also increase the risk of adverse drug events. We investigated utilization and dosing patterns of biologics during the first year of treatment only; future studies with more than 1 year of follow-up are needed, particularly to describe whether patients who experienced treatment modification during the first year are more or less likely to experience any other treatment modifications in subsequent years. In summary, we have shown that treatment modifications were common in the first year of treatment, affecting approximately one-third of patients with psoriasis receiving adalimumab, etanercept or ustekinumab. Concomitant use of conventional systemic therapies, particularly methotrexate, was frequent and should be considered when evaluating treatment response and adverse events to biologic therapies in real-world cohort studies. Data presented as n (%). Conventional systemic therapy used for > 120 days: conventional systemic therapy started before or at the time of initiation of biologic therapy and used concomitantly with the biologic for > 120 days. Bridging therapy: conventional systemic therapy started before or at the time of initiation of biologic therapy and used concomitantly with the biologic for ≤ 120 days. Rescue therapy: additional conventional systemic therapy required at least 120 days following the start of biologic therapy.
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